Pfizer Aktie

27,82EUR 0,01EUR 0,02%
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>

Aktionärsstruktur

Inhaber in %
Freefloat 99,94
The Vanguard Group, Inc. 8,06
Vanguard Group, Inc. (Subfiler) 7,62
SSgA Funds Management, Inc. 5,03
State Street Corp. 5,03
Capital Research & Management Co. (World Investors) 4,80
Wellington Management Co. LLP 4,43
Vanguard Total Stock Market Index Fund 2,83
BlackRock Fund Advisors 2,57
BlackRock Institutional Trust Co. NA 2,32
Vanguard 500 Index Fund 2,01
Geode Capital Management LLC 1,63
Washington Mutual Investors Fund 1,39
Vanguard Health Care Fund 1,32
Northern Trust Corp. 1,20

*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.

Personal

2016 2017 2018 2019 2020
Personal am Ende des Jahres 96 500 90 200 92 400 88 300 0
Umsatz pro Mitarbeiter in Mio. EUR 0,55 0,58 0,58 0,59 0,53

Bilanz (in Mio. EUR) - Aktiva

2016 2017 2018 2019 2020
Summe Umlaufvermögen 38 949 41 141 49 926 32 803 35 067
Summe Anlagevermögen 101 630 114 799 105 147 116 616 104 509
Summe Aktiva 171 615 171 797 159 422 167 489 154 229

Bilanz (in Mio. EUR) - Passiva

2016 2017 2018 2019 2020
Gesamtverschuldung/ -verbindlichkeiten 42 086 43 491 41 740 53 474 41 271
Summe Fremdkapital 111 775 100 141 95 664 104 044 90 756
Summe Eigenkapital 59 840 71 656 63 758 63 445 63 473
Summe Passiva 171 615 171 797 159 422 167 489 154 229

Adresse

235 East 42nd Street, 10017-5755 New York
Telefon +1 (212) 733-2323
Internet http://www.pfizer.com

Management

Albert Bourla
Chairman, Chief Executive & Operating Officer
Alexander Roderick MacKenzie
Chief Development Officer & Executive VP
Andy Schmeltz
President-US Oncology Business Unit
Angela Hwang
Group President-Biopharmaceuticals
Dan R. Littman
Independent Director
Dawn Rogers
Chief Human Resources Officer & EVP
Deborah Baron
Senior VP-Worldwide Business Development
Denise Bruns
Late-Phase Development Group Leader
Douglas Ernest Giordano
Senior VP-Worldwide Business Development
Douglas M. Lankler
Executive Vice President & General Counsel
Frank A. D'Amelio
Chief Financial Officer & EVP-Business Operations
Gordon Loh
Senior Vice President-Corporate Audit
Hakan Sakul
Vice President & Head-Diagnostics
Helen H. Hobbs
Independent Director
James C. Smith
Independent Director
James Quincey
Independent Director
Jennifer B. Damico
Senior VP-Controller & Accounting Officer
John D. Young
Chief Business Officer
John DeYoung
Vice President-Worldwide Business Development
Joseph J. Echevarria
Independent Director
Lidia L. Fonseca
Executive VP, Chief Digital & Technology Officer
Margaret M. Madden
Secretary, Chief Governance Counsel & Senior VP
Margaret McLoughlin
Executive Director-World Wide Business Development
Mikael Dolsten
Chief Scientific Officer
Monika A. Vnuk
Vice President-Worldwide Business Development
Rady A. Johnson
Chief Compliance & Risk Officer, Executive VP
Ronald E. Blaylock
Independent Director
Sally Susman
Chief Corporate Affairs Officer & Executive VP
Scott Gottlieb
Independent Director
Shantanu Narayen
Lead Independent Director
Susan J. Hockfield
Independent Director
Suzanne Nora Johnson
Independent Director
Tamas Koncz
Senior Medical Director